Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can nicotine patches and lozenges break the vaping habit?

NCT ID NCT07786896

Disease control Sponsor: West Virginia University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 26, 2026 · Last updated Aug 27, 2026 · Updated 1 time

Summary

This study explores whether nicotine replacement therapy (NRT)—using patches and lozenges—can help regular e-cigarette users stop vaping. Participants first vape as usual for three days, then are randomly assigned to either receive NRT for up to seven days or to quit all nicotine without NRT. Researchers track cravings, withdrawal symptoms, and nicotine exposure to see if NRT eases the quitting process and to improve future cessation methods.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Nicotine replacement therapy (nicotine patch and lozenge) combined with brief behavioral counseling
What this could lead to
If successful, this could point toward an effective, practical way to help people stop vaping, potentially reducing nicotine dependence and related health risks.
What could go wrong
This is a small, early-phase trial, so results may not apply to all vapers. NRT can cause side effects like dizziness or nausea, and some people may still struggle to quit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants will be at least 21 years of age * Report 5+ days per week of using a nicotine-containing ECIG that is a non-refillable pod-style (e.g., JUUL, Vuse Alto) or modern disposable (e.g., Elf Bar, PuffBar) for the past 6+ months. * Report smoking either \<100 lifetime cigarettes, or \>100 lifetime cigarettes but no regular smoking (some days or everyday) in the past year. * Current ECIG use will be confirmed via a semi-quantitative urinary cotinine value \> 4 (NicAlert), and current non-smoking status will be confirmed via an expired air CO level \<7ppm. * Must report an interest in quitting ECIGs within the next 1-6 months (Contemplation or Preparation Stage of Change; DiClemente et al 1991), but no use of pharmacotherapy (e.g., NRT, varenicline) within the past year. Exclusion Criteria: * Preference for ECIG liquid containing a substance other than nicotine (e.g., THC, cannabidiol) * Use of THC/cannabis \>15 days in past month, or being unwilling or unable to abstain from THC/cannabis during study conditions. * Use of non-cigarette tobacco (e.g., cigars, smokeless, hookah) on more than 5 days in the past month * Uncontrolled medical or psychiatric conditions, positive toxicology for illicit substances (e.g., cocaine, opiates, amphetamine) except THC * Alcohol use \>20 days in past month * Breastfeeding or positive pregnancy test.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cessation, nicotine are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Tobacco Use Cessation Vaping

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cessation, nicotine Cessation, tobacco E-cigarette use

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • East Carolina University

    Greenville, North Carolina, 27858, United States

  • West Virginia University, Life Sciences Building

    Morgantown, West Virginia, 26505, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.